Neurofeedback is Shown to Have Sustained Effects on ADHD
Many people are now aware that neurofeedback is effective in treating ADHD. In the world of neurofeedback research, there has up until this point been insufficient data concerning the duration of the benefits from neurofeedback therapy.
In a recent meta- analysis, which looked at 10 different studies involving 500 children ages 8-12, neurofeedback demonstrated sustained effect in the treatment of ADHD. This study looked at previous studies that were randomized, controlled, and also conducted follow-up for at least six months following the cessation of treatment.
For hyperactivity, impulsivity, and inattention, neurofeedback treatment produced lasting symptomatic relief, of at least 6 months. Although more studies are needed that follow neurofeedback patients for a longer duration, this meta- analysis shows promising and lasting results, validating neurofeedback as a curative therapy, as opposed to merely palliative.
Neurofeedback Shows Great Promise for Treatment- Resistant Depression
Treatment- resistant depression is defined as a lack of significant improvement after two adequate trials of two different antidepressants from two different pharmacologic classes.1
The National Institute of Mental Health (NIMH) estimates that 16.2 million U.S. adults had at least one major depressive episode in 2016. This is 6.7 percent of the U.S. adult population. Whereas most patients with major depression do respond well to treatment with antidepressants, 10%–30% of them do not. When the symptoms of a disease include functional impairment, depressed mood, poor quality of life, self-injurious behavior, and even suicide ideation and attempts, we are greatly in need of an effective therapy for treating these patients, preferably one that works fast!
In a recent pilot study, 8 of 12 patients responded to treatment, and five of those responded well enough to be classified as being in remission. There was also a control group in the study, which did not show significant improvement. This was a very small study, but the results were promising enough to call for more studies to be funded.
|1. Crown WH , Finkelstein S , Berndt ER , Ling D , Poret AW , Rush AJ et al. The impact of treatment-resistant depression on healthcare utilization and cost. J Clin Psychiatry. 2002;63 (11):963–71.|